Related Experiment Video
Updated: Jul 15, 2026

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
Targeting multiple arms of the apoptotic regulatory machinery
1Department of Medicine, Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia, USA.
Abstract:
ABT-737 targets Bcl-2/Bcl-xL but not Mcl-1, which confers resistance to this novel agent. Here, we summarize recent findings indicating that Mcl-1 represents a critical determinant of ABT-737 sensitivity and resistance, and that Mcl-1 down-regulation by various pharmacologic agents or genetic approaches dramatically increases ABT-737 lethality in diverse malignant cell types. These findings also show that the multidomain proapoptotic proteins Bax and Bak play important functional roles in ABT-737-mediated apoptosis, and that Bak activation is essential in potentiation of ABT-737 lethality by agents that down-regulate Mcl-1. Collectively, these findings suggest a novel therapeutic strategy targeting multiple arms of the apoptotic machinery.
Insights
Mcl-1 protein confers resistance to the novel agent ABT-737. Down-regulating Mcl-1 enhances ABT-737
Area of Science:
- Molecular Biology
- Cancer Research
- Drug Discovery
Background:
- ABT-737 is a novel agent targeting Bcl-2 and Bcl-xL.
- Resistance to ABT-737 can occur due to the Mcl-1 protein.
- Understanding Mcl-1's role is crucial for improving cancer therapy.
Purpose of the Study:
- To investigate the role of Mcl-1 in ABT-737 sensitivity and resistance.
- To explore strategies for overcoming Mcl-1-mediated resistance.
- To elucidate the involvement of Bax and Bak in ABT-737-induced apoptosis.
Main Methods:
- Review of recent findings on Mcl-1 and ABT-737.
- Analysis of pharmacologic and genetic approaches to down-regulate Mcl-1.
- Examination of the roles of Bax and Bak in apoptosis.
Main Results:
- Mcl-1 is a critical determinant of sensitivity and resistance to ABT-737.
- Down-regulation of Mcl-1 significantly increases ABT-737 lethality in cancer cells.
- Bak activation is essential for potentiation of ABT-737 by Mcl-1-targeting agents.
Conclusions:
- Mcl-1 down-regulation is a viable strategy to enhance ABT-737 efficacy.
- Targeting Mcl-1 and utilizing Bax/Bak pathways offers a novel therapeutic approach.
- Combined targeting of apoptotic machinery components may overcome drug resistance in cancer.
Related Concept Videos
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Cellular Injury V: Apoptosis and Autophagy
Caspases
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

